Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

October 10, 2017

Primary Completion Date

April 24, 2018

Study Completion Date

August 9, 2019

Conditions
InfluenzaVaccine
Interventions
BIOLOGICAL

cH8/1N1 LAIV

"Live-attenuated influenza virus vaccine (LAIV) expressing chimeric hemagglutinin (HA) with the H8 head and H1 stalk and neuraminidase (NA) subtype 1 (N1) (cH8/1N1):~HA head, A/mallard/Sweden/24/2002 (H8N4); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1) containing the backbone of the cold-adapted/temperature sensitive of the Russian LAIV A/Leningrad/134/17/1957 (Len17 IDCDCRG46D).~Administered intranasally as drops at a dose of 10⁷·⁵ (plus or minus ⁰·⁵) 50% egg infectious dose (EID50), formulated in a total volume of 0.5 mL sterile saline (0.25 mL per nostril)."

BIOLOGICAL

AS03-adjuvanted cH5/1N1 IIV

"Chimeric H5 head with H1 stalk plus N1 (cH5/1N1) split virion inactivated influenza virus vaccine (IIV) plus AS03 adjuvant: HA head, A/Vietnam/1203/2004 (H5N1); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1).~Administered intramuscularly at a dose of 15 μg of hemagglutinin in a volume of 0.5 mL of phosphate buffered saline (PBS)."

BIOLOGICAL

cH5/1N1 IIV

"Chimeric H5 head with H1 stalk plus N1 (cH5/1N1) split virion inactivated influenza virus vaccine (IIV):~HA head, A/Vietnam/1203/2004 (H5N1); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1).~Administered intramuscularly at a dose of 15 μg of hemagglutinin in a volume of 0.5 mL of phosphate buffered saline (PBS)."

BIOLOGICAL

AS03-adjuvanted cH8/1N1 IIV

"Chimeric H8 head with H1 stalk plus N1 (cH8/1N1) inactivated influenza vaccine plus AS03 adjuvant: HA head, A/mallard/Sweden/24/2002 (H8N4); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1).~Administered intramuscularly at a dose of 15 μg of hemagglutinin in a volume of 0.5 mL of phosphate buffered saline (PBS)."

BIOLOGICAL

Normal saline

Administered intranasally as 0.25 mL nasal drops per nostril

BIOLOGICAL

Phosphate buffered saline (PBS)

Administered intramuscularly as 0.5 mL injection

Trial Locations (2)

27710

Duke University, Durham

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

Sponsors
All Listed Sponsors
collaborator

Icahn School of Medicine at Mount Sinai

OTHER

collaborator

Children's Hospital Medical Center, Cincinnati

OTHER

collaborator

Duke University

OTHER

collaborator

The Emmes Company, LLC

INDUSTRY

collaborator

GlaxoSmithKline

INDUSTRY

lead

PATH

OTHER